Core Insights - Hologic (HOLX) and Align Technology (ALGN) are prominent players in the medical technology market, each focusing on different niches [1][2][3] Hologic (HOLX) - Hologic's Diagnostics division saw a revenue decline of 3.5% in Q1 2026, primarily due to reduced sales of COVID-19 tests and legacy STI assays, although this was partially offset by stronger sales of other assays [4] - The company received FDA clearance and CE-IVDR approval for its new Panther Fusion Gastrointestinal Bacterial Assays, and the Breast Cancer Index test is gaining traction [5] - Hologic's acquisition of Endomagnetics in 2024 contributed to a 1.8% revenue growth in the Breast Health segment, and the company plans to launch the Envision Mammography Platform this year [6] - The GYN Surgical division experienced an 8.7% year-over-year sales increase, driven by the Gynesonics acquisition and higher sales of MyoSure devices [7] - Hologic is nearing completion of an $18.3 billion take-private deal, with a cash offer of $76 per share representing a 46% premium over the May 23 closing price [8] Align Technology (ALGN) - Align Technology achieved record revenues of $4 billion in 2025, with clear aligner volumes increasing by 6.7% year-over-year, supported by strong performance in various global regions [9][10] - The company is focusing on growth through Dental service organizations (DSOs), which are expanding faster than traditional practices, enhancing the adoption of its products [10][11] - Align's product strategy includes lower upfront cost options, which are broadening access for doctors and supporting margins, with over 296,000 active Invisalign-trained doctors treating more than 22 million patients [12] - The company's cash and cash equivalents stood at $1.09 billion with zero debt as of the end of 2025 [13] Earnings Projections - The Zacks Consensus Estimate for Hologic's fiscal 2026 earnings indicates a 5.4% year-over-year growth to $4.49, with recent downward revisions [14] - In contrast, Align Technology's EPS for 2026 is projected to grow by 6.7% to $11.21, with upward revisions in the past 60 days [15] Price Performance & Valuation - Over the past three months, Hologic shares increased by 1.5%, while Align Technology shares surged by 13.2% [16] - Hologic trades at a forward price-to-sales (P/S) ratio of 3.86X, slightly above its median, whereas Align Technology's P/S ratio of 3.02X is below its median [17]

Company Overview - Align Technology, Inc. (ALGN) is a leader in the medical device sector, valued at a market cap of $12.1 billion, and is headquartered in Tempe, Arizona [1] - The company is known for pioneering the digital transformation of orthodontics with its flagship product, the Invisalign system, and operates an integrated "Align Digital Platform" [1] Market Position - ALGN is classified as a "large-cap stock" due to its market cap exceeding $10 billion, highlighting its size and influence in the medical instruments & supplies industry [2] - The company has treated over 22 million patients globally and is expanding its ecosystem with products like iTero intraoral scanners and exocad CAD/CAM software [2] Stock Performance - Currently, ALGN is trading 18.7% below its 52-week high of $208.31, reached on July 29, 2025, but has seen a 4% increase over the past three months, outperforming the Nasdaq Composite's 3.2% decline [3] - Year-to-date, ALGN shares are up 8.5%, while the Nasdaq Composite has fallen by 3.7% [5] - Over the past 52 weeks, ALGN has gained 2%, which is significantly lower than the Nasdaq Composite's 26% increase [5] Technical Analysis - ALGN has been trading above its 200-day moving average since early January, although it has recently started trading below its 50-day moving average since early March [5] Financial Performance - In Q4, ALGN reported revenue of $1.05 billion, a 5.3% year-over-year increase, slightly beating analyst expectations of $1.03 billion [7] - The adjusted EPS for the quarter climbed 34.8% to $3.29, surpassing the consensus estimate of $2.97, driven by strong demand for clear aligners and traction in dental service organizations [7]

Core Insights - Align Technology, Inc. (ALGN) specializes in designing and marketing Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners, with a market capitalization of approximately $13.6 billion [1] Stock Performance - Over the past 52 weeks, ALGN stock has decreased by 4.1%, while the S&P 500 Index has increased by roughly 13%, indicating underperformance relative to the broader market [2] - In 2026, ALGN stock has rebounded with a year-to-date increase of 21.7%, contrasting with a marginal gain in the S&P 500 Index, suggesting renewed investor confidence [2] Sector Comparison - The State Street Health Care Select Sector SPDR ETF (XLV) has risen by 6.5% over the last 52 weeks, outperforming ALGN during that period; however, ALGN has surpassed the ETF's 1.3% gain in 2026 [3] Earnings Report - Following the release of Q4 fiscal 2025 earnings on February 4, ALGN stock experienced a 2.7% increase on the announcement day, followed by gains of 8.9% and 6.8% in the subsequent trading sessions [6] - Revenue for Q4 fiscal 2025 grew by 5.3% year over year to $1.05 billion, exceeding analyst expectations of $1.03 billion [6] - Adjusted EPS rose by 34.8% to $3.29, surpassing the Street estimate of $2.97 [6] Growth Drivers - The growth in revenue was driven by strong performance within dental service organizations (DSOs) and significant increases in clear aligner volumes [7] - Management is focusing on global expansion and increasing orthodontic usage among children and teenagers, which supports a positive outlook for stable end-market conditions [7] Future Expectations - For fiscal year 2026, analysts project diluted EPS to increase by 7.3% year over year to $9.08, indicating steady earnings momentum [8] - Align has exceeded EPS estimates in three of the past four quarters, with only one miss [8] - The overall rating for ALGN stock is "Moderate Buy," with eight out of 15 analysts issuing a "Strong Buy" rating, six recommending "Hold," and one suggesting "Moderate Sell" [8]

Core Insights - Giverny Capital Asset Management's portfolio returned 0.01% in Q4 2025, underperforming the S&P 500's 2.66% return, and YTD returns were 12.58% compared to the Index's 17.88% [1] - The firm faced challenges due to underweighting in large technology companies and overweighting in smaller niche leaders, despite strong earnings growth and capital returns from portfolio companies [1] - The market's focus on AI investments has overshadowed the actual benefits of portfolio companies, impacting overall performance [1] Company Insights - Align Technology, Inc. (NASDAQ:ALGN) was highlighted in Giverny Capital Asset Management's Q4 2025 investor letter, noting a one-month return of 5.18% but a 52-week loss of 25.10% [2] - As of January 29, 2026, Align Technology's stock closed at $164.12 per share, with a market capitalization of $11.896 billion [2] - The company is recognized for its innovative product, Invisalign clear aligners, which are expected to gradually replace traditional braces, potentially impacting the orthodontist profession [3]

Company Overview - Align Technology, Inc. (ALGN) has a market capitalization of $11.2 billion and specializes in developing and providing Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services globally [1] Financial Performance - The company is expected to announce its fiscal Q4 2025 results on February 4, with analysts predicting earnings of $2.47 per share, reflecting a 26% increase from $1.96 per share in the same quarter last year [2] - For fiscal 2025, analysts forecast an EPS of $8.18, which represents a 16.7% increase from $7.01 in fiscal 2024 [3] - Following the Q3 2025 results on October 29, ALGN shares rose by 4.9%, with adjusted EPS reported at $2.61 and revenue at $995.7 million, surpassing consensus estimates [5] Market Performance - Over the past 52 weeks, ALGN stock has declined by 22.5%, underperforming the S&P 500 Index, which rose by 16.2%, and the State Street Health Care Select Sector SPDR ETF, which returned 13.3% [4] Analyst Sentiment - The consensus rating for ALGN stock is "Moderate Buy," with 15 analysts providing coverage: eight rated it as "Strong Buy," six as "Hold," and one as "Moderate Sell" [6] - The average analyst price target for ALGN is $171.38, indicating a potential upside of 2.2% from current levels [6]

Company Overview - Align Technology, Inc. (ALGN) is based in Tempe, Arizona, and specializes in designing, manufacturing, and marketing Invisalign clear aligners and iTero intraoral scanners for orthodontists and general practitioners [1] - The company has a market capitalization of $11.4 billion, categorizing it as a large-cap stock, which reflects its significant size and influence in the medical instruments and supplies industry [2] Market Performance - ALGN's stock has experienced a decline of 33.1% from its 52-week high of $246.19, reached on December 11, 2024 [3] - Over the past three months, ALGN stock has gained 23.8%, outperforming the S&P 500 Index, which saw a gain of 5.4% during the same period [3] - In the longer term, ALGN shares have fallen 12.5% over six months and 30.6% over the past 52 weeks, significantly underperforming the S&P 500's six-month gains of 14% and 14.1% over the last year [4] Recent Financial Results - On October 29, ALGN reported its Q3 results, with an adjusted EPS of $2.61, exceeding Wall Street expectations of $2.37 [5] - The company's revenue for the quarter was $995.7 million, surpassing forecasts of $971.5 million [5] Competitive Landscape - ALGN's main competitor, DENTSPLY SIRONA Inc. (XRAY), has underperformed, with a 29% decline over six months and a 40.4% drop over the past 52 weeks [5] Analyst Sentiment - Wall Street analysts maintain a reasonably bullish outlook on ALGN, with a consensus "Moderate Buy" rating from 15 analysts [6] - The mean price target for ALGN is $174.54, indicating a potential upside of 6.1% from current price levels [6]

Core Insights - Align Technology, Inc. showcased its latest innovations in digital dentistry at the Greater New York Dental Meeting (GNYDM) 2025, emphasizing its commitment to enhancing treatment planning and patient experiences through advanced technology [1] Company Innovations - Align Technology presented the Align™ Digital Platform, which integrates software, systems, and services for a seamless workflow among doctors, labs, patients, and consumers [1] - The iTero Lumina™ scanner was highlighted for its 3x larger field of view and ability to scan 2x faster, improving efficiency in capturing complex dental cases [1] - The Align™ Oral Health Suite was introduced, featuring tools for personalized oral health reports to enhance patient engagement [1] - Invisalign Smile Architect™ software now includes Multiple Treatment Plans, allowing for side-by-side comparison of orthodontic and restorative options [1] - The iTero™ Design Suite aims to improve practice efficiency and patient experiences by streamlining the design process for in-practice 3D printing [1] - ClinCheck® Signature experience offers a faster, tailored approach to treatment planning, enhancing the overall workflow for dental professionals [1] Educational Initiatives - Align Technology sponsored clinical education sessions led by industry experts, focusing on practice productivity, diagnosis simplification, and modern patient education [1]

Core Insights - Meridian Growth Fund's third-quarter 2025 performance was negatively impacted by sector positioning and strict investment discipline, resulting in a return of -1.78% compared to the Russell 2500 Growth Index's 10.73% return [1] Company Overview: Align Technology, Inc. (NASDAQ:ALGN) - Align Technology, Inc. is a leader in dental technology, known for its Invisalign clear aligners and iTero intraoral scanners [3] - The stock experienced a one-month return of 6.25% but has lost 37.14% over the past 52 weeks, closing at $147.19 with a market capitalization of $10.669 billion on November 28, 2025 [2] Financial Performance - In Q3 2025, Align Technology reported revenue of $995.7 million, reflecting a 1.7% decline from the previous quarter but a 1.8% increase year-over-year [4] Market Dynamics - The company faced challenges with demand rebound expectations not materializing, particularly in the teen segment where revenue growth slowed to 3% [3] - Market share gains reversed due to a weaker macroeconomic environment affecting discretionary dental procedures and a shift towards lower-cost alternatives [3] Investment Sentiment - Align Technology was held by 48 hedge fund portfolios at the end of Q3 2025, a decrease from 54 in the previous quarter, indicating a decline in popularity among hedge funds [4] - Despite its potential, the company is viewed as less favorable compared to certain AI stocks that are perceived to offer greater upside potential and lower downside risk [4]

Core Insights - Align Technology, Inc. has a market capitalization of $10.2 billion and is recognized for its Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners, providing advanced orthodontic and restorative digital solutions globally [1] Stock Performance - Over the past 52 weeks, Align Technology's shares have decreased by 37.5%, underperforming the S&P 500 Index, which gained 11% during the same period [2] - Year-to-date, the stock has dropped 31.6%, while the S&P 500 has risen by 12.3% [2] Recent Financial Results - Following the Q3 2025 results released on October 29, shares surged by 4.9%, with adjusted EPS at $2.61 and revenue reaching $995.7 million, surpassing consensus estimates [4] - Align Technology raised its Q4 revenue forecast to between $1.03 billion and $1.05 billion, anticipating mid-single-digit growth in Clear Aligner volumes [4] Earnings Expectations - For the fiscal year ending December 2025, analysts project a 16.7% year-over-year increase in EPS to $8.18 [5] - The company's earnings surprise history is mixed, with two beats and two misses in the last four quarters [5] Analyst Ratings - Among 14 analysts covering Align Technology, the consensus rating is a "Moderate Buy," consisting of eight "Strong Buy" ratings, five "Holds," and one "Moderate Sell" [5] - This rating configuration is slightly less bullish than three months ago, which had nine "Strong Buy" ratings [6] Price Targets - Evercore ISI raised its price target on Align Technology to $170, maintaining an "Outperform" rating [7] - The mean price target of $173.25 indicates a potential upside of 21.5% from the current price, while the highest target of $205 suggests a 43.8% upside [7]

Company Overview - Align Technology's shares were priced at $133.14 as of October 28, 2025, with a market capitalization of $9.65 billion [3] - The company reported trailing twelve-month (TTM) revenue of $3.96 billion and net income of $437.61 million [3] - Align Technology primarily generates revenue from Invisalign clear aligners and iTero intraoral scanners, serving orthodontists, general dentists, and dental specialists [4] Business Model - The business model is based on the sale of orthodontic treatment systems and related digital solutions, with recurring revenue from software, services, and ancillary products [4] - Align Technology operates at scale with over 21,000 employees and a diversified geographic footprint, targeting both adult and pediatric patients [5] Market Position - Despite competition, Align Technology maintains a significant market share, having shipped 647,800 cases in the third quarter, representing a 4.9% year-over-year increase [7][8] - The company is the only one allowed to market the Invisalign System, although it faces competition from companies like Angelalign Technology, which reported a 46.7% increase in global case volume in 2024 [7][8] Financial Performance - Align Technology's trailing 12-month revenue is approximately 1.2% lower than its peak in early 2022, indicating stagnation in the Invisalign business [6] - Earnings per share have decreased by 78% from a peak reached over five years ago, highlighting disappointing bottom-line performance [7] Recent Developments - Navera Investment Management Ltd. reduced its stake in Align Technology by 785,194 shares, valued at approximately $122.99 million, retaining only 2,365 shares post-sale [1][2] - As of the filing date, Align Technology's shares had underperformed the S&P 500 by 57.93 percentage points, down 38.3% over the past year [2]